Abstract
2 min readKEB has served on advisory boards for Neuralstem and Dainippon Sumitomo Pharma. CB has received grant support from Pfizer, Lundbeck and Takeda, and acts as a consultant for Boehringer Ingelheim, Lundbeck and Pfizer. PH has received consulting fees or travel reimbursements from Allergan, Alkermes, Akili, Biogen, Boehringer Ingelheim, Forum Pharma, Genentech (Roche Pharma), Intra-Cellular Therapies, Jazz Pharma, Lundbeck Pharma, Minerva Pharma, Otsuka America (Otsuka Digital Health), Sanofi Pharma, Sunovion Pharma, Takeda Pharma, and Teva, within the last 3 years. He receives royalties from the Brief Assessment of Cognition in Schizophrenia and the MATRICS Consensus Battery. He is chief scientific officer of i-Function, Inc. He has a research grant from Takeda and from the Stanley Medical Research Foundation. SL has received consulting fees from EPI-Q, Cogstate LTD, and Gift of Hope, all unrelated to this work. MM has consulted with and receives research support from Janssen Pharmaceuticals in the last 3 years. He has consulted with Otsuka Pharmaceuticals. He is a co-owner of priori ai, LLC. KM has received consultancy fees from Lundbeck, Janssen and Allergan in the past 3 years. RP has received support for travel to scientific meetings from Lundbeck and Servier. He uses scientific software for research provided free of charge by SBT-pro. TVR has received grant funding from the National Health and Medical Research Council, Club Melbourne, the Henry Freeman Trust, Jack Brockhoff Foundation, University of Melbourne, Barbara Dicker Brain Sciences Foundation, Rebecca L Cooper Foundation and the Society of Mental Health Research. TS has received honoraria for advisory board, consultations, and/or speaker's role from Dainippon Sumitomo Pharmaceutical, Otsuka Pharmaceutical, Mochida Pharmaceutical, Takeda Pharmaceutical, and NeuroCog Trials Co. Ltd. IT has received research funding from the Canadian Institutes of Health Research (CIHR) and has served as consultant to Dainippon Sumitomo and Lundbeck Canada. EV has received grants and served as consultant, advisor or CME speaker for the following entities: AB-Biotics, Abbott, Allergan, Angelini, AstraZeneca, Bristol-Myers Squibb, Dainippon Sumitomo Pharma, Farmindustria, Ferrer, Forest Research Institute, Gedeon Richter, Glaxo-Smith-Kline, Janssen, Lundbeck, Otsuka, Pfizer, Roche, SAGE, Sanofi-Aventis, Servier, Shire, Sunovion, Takeda, the Brain and Behaviour Foundation, the Spanish Ministry of Science, Universities and Innovation (CIBERSAM), the Seventh European Framework Programme and Horizon 2020, the Brain and Behaviour Foundation (NARSAD) and the Stanley Medical Research Institute. LY has been a member of advisory boards, received research grants, or been a speaker for Allergan, Alkermes, Astrazeneca, Bristol Myers Squibb, Canadian Institutes of Health Research, Canadian Foundation for Innovation, Dainippon Sumitomo Pharma, GSK, Janssen, Lilly, NARSAD, Otsuka, Pfizer, Servier, Stanely Foundation, Sunovion and Teva. AY is supported by National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health. AC, BL, KEL, CL and AM have no conflicts associated with this work.
Discussion(0)
No comments yet. Be the first to comment.